Table 1.

Baseline characteristics of the study population according to tertiles of eGFRa

CharacteristiceGFR (ml/min per 1.73 m2) (N = 767)P (Trend)
≥64(n = 255)56 to 64(n = 256)<56(n = 256)
Age (yr)67.7 ± 7.067.8 ± 7.170.0 ± 7.0<0.001
Gender (M/F)124/131126/130133/1230.72
Serum creatinine (μmol/L)84 ± 1093 ± 9108 ± 20<0.001
eGFR (ml/min per 1.73 m2)73 ± 860 ± 249 ± 5<0.001
Microalbuminuria (%)1414190.16
UACR (mg/mmol)1.5 ± 2.91.4 ± 2.81.7 ± 3.10.48
HbA1c (%)6.1 ± 0.86.0 ± 0.76.2 ± 0.80.08
Type 2 diabetes (%)3841400.53
Impaired glucose metabolism (%)2319280.07
Normal glucose metabolism (%)3940320.08
BMI (kg/m2)26.0 ± 3.427.8 ± 4.129.2 ± 4.4<0.001
Waist-to-hip ratio0.92 ± 0.090.94 ± 0.100.94 ± 0.090.01
Brachial BP (mmHg)
    SBP140 ± 20143 ± 19146 ± 200.01
    DBP77 ± 978 ± 978 ± 90.09
    MAP98 ± 12100 ± 11101 ± 110.01
    PP64 ± 1566 ± 1468 ± 160.01
Hypertension (%)627276<0.001
Antihypertensive medication (%)263850<0.001
Total serum cholesterol (mmol/L)5.7 ± 1.05.7 ± 1.15.7 ± 1.00.81
Total serum LDL (mmol/L)3.6 ± 0.93.6 ± 0.93.6 ± 0.90.72
Total serum HDL (mmol/L)1.5 ± 0.41.4 ± 0.41.3 ± 0.4<0.001
Total serum triglycerides (mmol/L)1.4 ± 0.81.5 ± 0.71.7 ± 1.0<0.001
Lipid-lowering medication (%)1714190.59
Previous CVD (%)4745510.51
Current smoking (%)1915110.01
  • a Data are total numbers, means ± SD, or percentage. Microalbuminuria was defined as UACR between 2 and 30 mg/mmol. BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic BP; HbA1c, glycosylated hemoglobin; MAP, mean arterial pressure; PP, pulse pressure; SBP, systolic BP; UACR, urinary albumin-creatinine ratio.